Comments
Divis Laboratories has filed a detailed response within the permitted time to the observations made by the US health regulator after inspection of the drug firm’s manufacturing plant at Visakhapatnam in Andhra Pradesh.
“The company has already filed its detailed response to the ‘Form 483’ observations of the USFDA within the time permitted,” Divis Laboratories today said in a regulatory filing.
Last month, the US health regulator had made five observations after inspection of the company’s manufacturing plant at Visakhapatnam.
Divis Laboratories had set up its second manufacturing facility at Visakhapatnam (Unit-II) in 2002 on a 350-acre site.
The site has 14 multi-purpose production blocks. The company manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at the plant.
Shares of the company were were trading 0.33 down at Rs 735.05 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.